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Common cancer therapies employ chemicals or radiation that damage DNA. Cancer and 
normal cells respond to DNA damage by activating complex networks of DNA damage 
sensor, signal transducer, and effector proteins that arrest cell cycle progression, and 
repair damaged DNA. If damage is severe enough, the DNA damage response (DDR) 
triggers programed cell death by apoptosis or other pathways. Caspase 3 is a protease 
that is activated upon damage and triggers apoptosis, and production of prostaglandin 
E2 (PGE2), a potent growth factor that can enhance growth of surviving cancer cells 
leading to accelerated tumor repopulation. Thus, dying tumor cells can promote growth 
of surviving tumor cells, a pathway aptly named Phoenix Rising. In the present study, 
we surveyed Phoenix Rising responses in a variety of normal and established cancer 
cell lines, and in cancer cell lines freshly derived from patients. We demonstrate that IR 
induces a Phoenix Rising response in many, but not all cell lines, and that PGE2 pro-
duction generally correlates with enhanced growth of cells that survive irradiation, and 
of unirradiated cells co-cultured with irradiated cells. We show that PGE2 production is 
stimulated by low and high LET ionizing radiation, and can be enhanced or suppressed 
by inhibitors of key DDR proteins. PGE2 is produced downstream of caspase 3 and 
the cyclooxygenases COX1 and COX2, and we show that the pan COX1–2 inhibitor 
indomethacin blocks IR-induced PGE2 production in the presence or absence of DDR 
inhibitors. COX1–2 require oxygen for catalytic activity, and we further show that PGE2 
production is markedly suppressed in cells cultured under low (1%) oxygen concentra-
tion. Thus, Phoenix Rising is most likely to cause repopulation of tumors with relatively 
high oxygen, but not in hypoxic tumors. This survey lays a foundation for future studies to 
further define tumor responses to radiation and inhibitors of the DDR and Phoenix Rising 
to enhance the efficacy of radiotherapy with the ultimate goal of precision medicine 
informed by deep understanding of specific tumor responses to radiation and adjunct 
chemotherapy targeting key factors in the DDR and Phoenix Rising pathways.
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inTrODUcTiOn
The majority of cancer patients receive radiotherapy (RT), and 
virtually all cancer treatments employ chemical or physical 
genotoxins that directly damage DNA, or inhibit DNA metabo-
lism (such as topoisomerase inhibitors). DNA damage activates 
DNA damage response (DDR) pathways, but the specific 
DDR pathways activated, the degree of activation, and cell 
fate depend on many factors, including the amount and type 
of damage, as well as the genetic and environmental state of 
the cell (cell type, cell cycle phase, normal vs. tumor, hypoxic 
vs. normoxic, etc). Low and high LET IR yield different dose 
distributions in tissue and induce different types of damage, and 
may, thus, differentially activate DDR pathways. Solid tumors 
are genetically heterogeneous, which contributes to therapeutic 
resistance (1), and it is difficult to achieve 100% elimination 
of tumor cells while minimizing normal tissue toxicity. Rare 
surviving tumor cells, thus, pose a risk of tumor repopulation. 
A long recognized problem is that following RT, tumors may be 
rapidly repopulated, a phenomenon termed “accelerated tumor 
repopulation.” The Li lab identified a paracrine growth factor 
signaling pathway that contributes to accelerated repopulation 
called “Phoenix Rising” (2–4). This pathway is initiated when 
lethally irradiated tumor cells activate caspase 3/7 (a key step 
in caspase-dependent apoptosis), leading to production of 
prostaglandin E2 (PGE2), a potent growth factor (Figure 1A). 
Thus, dying cells trigger growth of neighboring viable cells, a 
process akin to wound healing. PGE2 produced via Phoenix 
Rising stimulates cell growth in culture and tumor repopula-
tion in mice (2). Given the high radiation doses required to kill 
high fractions of tumor cells, the rare surviving cells are likely 
to experience significant DNA damage, and rapid proliferation 
of such cells is expected to enhance mutagenesis and may drive 
tumor progression toward a more aggressive metastatic state. 
There is accumulating evidence that PGE2/Phoenix Rising is 
clinically relevant. Patients with head and neck squamous cell 
carcinoma or breast cancers that express caspase 3 show reduced 
survival (2), PGE2 promotes renal carcinoma cell invasion that 
may contribute to metastasis (5), and recent studies indicate 
that blocking PGE2 production with cyclooxygenase inhibitors 
improves outcomes in bladder and breast cancer patients treated 
with chemotherapy or RT (6, 7).
The DDR comprises complex networks of DNA repair and 
DNA damage signaling (checkpoint) pathways that control 
cell fate in response to DNA damage; a simplified view of DDR 
responses to ionizing radiation is shown in Figure 1B. The most 
fundamental cell fate decision is survival vs. death. Central to the 
DDR are protein kinases, including upstream PI3-like kinases 
ATM, ATR, and DNA-PKcs, that converge on downstream 
checkpoint kinases Chk1 and Chk2 (8). When cells experience 
limited damage, these factors promote cell survival and sup-
press cancer by effecting cell cycle arrest, stimulating repair, 
and promoting genome stability. Above a certain DNA damage 
threshold, these pathways promote senescence or programed 
cell death by apoptosis, necrosis, or autophagy (9, 10). Thus, 
DDR pathways are not “on or off ” but show graded responses 
depending on the level of damage, and DDR thresholds are 
known to be genetically regulated (11, 12), and may vary for each 
checkpoint (13). There is substantial crosstalk among checkpoint 
and DNA repair pathways (14–22), and a major goal in the field 
is to identify synthetic (genetic) lethal interactions to exploit in 
cancer therapy (23).
There is considerable interest in targeting DDR proteins to 
augment therapeutic responses to chemotherapy and/or RT 
(24–26), for example, by sensitizing tumor cells to DNA dam-
age. A common goal in cancer therapy is to kill tumor cells by 
inducing apoptosis. However, increasing caspase 3-dependent 
apoptosis may be a double-edged sword, leading initially to 
increased tumor killing, but accompanied by increased PGE2 
secretion and subsequent growth stimulation of rare surviv-
ing tumor cells. The present study was designed to determine 
whether modulating the DDR (by chemical inhibition of DNA-
PKcs, ATM, or Chk1) influences Phoenix Rising in a variety 
of normal or tumor cells following exposure to low and high 
LET IR. Phoenix Rising can be blocked at many steps along the 
pathway from caspase-3 cleavage, to PGE2 production/receptor 
binding (2, 27), and we tested whether chemical inhibition of 
COX1 and COX2 (COX1–2) blocked PGE2 production. Certain 
tumors are hypoxic, and because oxygen is a necessary co-factor 
for COX1–2 activity, we also tested whether PGE2 production 
differed under normoxic vs. hypoxic conditions. We show that 
PGE2 production, and proliferation of co-cultured unirradi-
ated cells vary widely among cell lines. In some cell lines, we 
observed enhanced PGE2 production with inhibition of DNA-
PKcs, suppression by inhibition of ATM, and both COX1–2 
inhibition and hypoxia robustly suppressed PGE2 production. 
In general, PGE2 production did not affect short-term growth of 
irradiated cells (up to 48 h post IR), but PGE2 levels correlated 
with growth of co-cultured, unirradiated cells in longer-term 
growth assays. Interestingly, both oxygen concentration and 
LET alter PGE2 production. Together, these findings suggest 
that RT of certain tumor types may be enhanced by specific 
combinations of DDR and/or COX1–2 inhibitors that enhance 
tumor cell killing and mitigate accelerated tumor repopulation.
MaTerials anD MeThODs
cell culture and chemical inhibitors
Human cell lines HeLa, HT1080, HCT116, MCF7, BJ1hTERT, 
and HFL3, and mouse melanoma D17 cells, were cultured in 
Dulbecco’s minimal essential medium (DMEM, Gibco) with 
10% fetal bovine serum (Sigma or Atlas Biologicals), 100  IU/
mL penicillin, 100 μg/mL streptomycin, 2.5 μg/mL amphotericin 
B (antibiotic/antimycotic, LifeTechnologies), 1  mM sodium 
pyruvate (Gibco) and incubated at 37°C with 5% CO2 in air. 
For the hypoxia experiments, HeLa cells were maintained in a 
hypoxic incubator in the same media and growth conditions 
except that the oxygen concentration was limited to 1%. Primary 
head and neck tumor [patient-derived xenograft (PDX)] cell 
lines CUHN013, CUHN036 (28), CUHN065, and CUHN067 
were cultured in Rhesus Monkey Kidney, Mucaca mulatta (RMK) 
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primary cell line media consisting of DMEM:F12 (3:1) with 
10% FBS, insulin (5 μg/mL), hEGF (10 ng/mL), hydrocortisone 
(0.4 μg/mL), transferrin (5 μg/mL), penicillin (200  units/mL), 
and streptomycin (200 μg/mL).
Inhibitors of ATM (KU55933), Chk1 (UCN-01) DNA-PKcs 
(NU7026), and COX1–2 [indomethacin (Indo)] were purchased 
from Tocris Bioscience or Sigma and stored in powdered form at 
−20 or 4°C (NU7026). All compounds were freshly solubilized 
in DMSO to 100× working concentrations immediately prior to 
addition to cell cultures. Master mixes containing 1× final con-
centration of inhibitors in fresh media were prepared and added 
to wells pre- and post-irradiation. Final inhibitor concentrations 
were: 10 μM for ATMi, DNA-PKi, and COX1–2i, and 100 nM 
for Chk1i.
human-Derived head and neck 
squamous cell carcinoma cell lines
Head and neck squamous cell carcinoma patients were consented 
at the University of Colorado Hospital in accordance with the 
protocol approved by the Colorado Multiple Institutional 
Review Board (COMIRB #: 08-0552). CUHN013, CUHN065, 
and CUHN067 cell lines were derived directly from fresh patient 
post-surgical tumor tissue. Due to minimal tissue procured, 
the CUHN036 cell line required expansion and was, therefore, 
derived from PDX tumors. Tumor tissue was processed into 
~2 mm × 2 mm × 2 mm pieces using a scalpel and forceps and 
FigUre 1 | (a) Phoenix Rising pathway of accelerated tumor repopulation. The cascade is initiated by cleavage and activation of caspase 3, which also promotes 
programed cell death by apoptosis. Activated caspase 3 cleaves and activates phospholipase 2 that hydrolyzes fatty acid phospholipid bonds, releasing arachidonic 
acid and lysophospholipids. Arachidonic acid is converted to PGH2 by COX1 and COX2 peroxidases in the presence of oxygen; this step can be blocked by 
COX1–COX2 inhibitor indomethacin or hypoxia. Prostaglandin synthases generate the family of prostanoids, including PGD2, PGE2, and PGF2. PGE2 (and possibly 
other PGs) excreted from dying cells promote growth of surviving cells, accelerating tumor repopulation. (B) The DDR regulates cell fate after radiation damage. 
Proteins involved in DNA repair and damage checkpoint pathways crosstalk with programed cell death pathways to determine a variety of short- and long-term cell 
fates. Phoenix Rising and the DDR are linked through apoptosis and possibly other processes.
two to three pieces were placed in wells of cell culture grade 
six-well dishes without media. Uncovered plates were placed in 
the back of a cell culture hood and tumor pieces were allowed 
to dry/adhere to the plate for 15 min, then 2 mL of RMK media 
was added to each well. Fresh media was added to tumor slices 
twice per week.
Outgrowing cells were characterized by flow cytom-
etry (Cyan-ADP, Beckman Coulter) to confirm the presence 
of epithelial cancer cells (anti-CD44-APC, anti-EPCAM-FITC, 
anti-EGFR-PE) within the cancer-associated fibroblast cells 
(anti-mouse H2kd-PerCP–Cy5.5 for PDX tissue). Once cell 
populations had expanded sufficiently (~107 cells), cells were 
sorted (MoFlo-XDP, Beckman Coulter) twice in succession 
using the above combination of cell surface markers to eliminate 
contaminating fibroblasts. To confirm the origin of resulting 
cell lines, we conducted short tandem repeat (STR) analysis 
comparing sorted cells to the originating patient tissue. Finally, 
tumors generated in immune-compromised nude mice from 
these human-derived cell lines recapitulated the morphology 
and histology of the original patient or PDX tumors.
Pge2 Detection by elisa
Cells (10,000–20,000) were seeded into individual wells of 
96-well microtiter dishes and incubated overnight using two to 
three replicate wells per treatment group. The dishes were irradi-
ated with 10 Gy γ-rays (CSU, 137Cs source), or 3 or 10 Gy X-rays 
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(NIRS) low LET IR. The cells were treated with either DDR or 
COX-1/COX-2 inhibitors 12–16 h prior to IR and the inhibitors 
were present in the media during and after IR. PGE2 concentra-
tions in growth media were measured at 0, 24, and 48 h after IR 
using a PGE2 Parameter ELISA kit (R & D Systems) according 
to the manufacturer’s directions. PGE2 standard concentration 
curves (Figure S1 in Supplementary Material) were derived from 
dilutions of pure PGE2 (R & D Systems) and fit to asymmetric 
5-parameter logistic non-linear regressions using Prism software 
(Graphpad).
cell Proliferation assay
Cell proliferation was measured using sulforhodamine B (SRB) 
assays (29) performed on cells adhering to PGE2 assay plates, 
since PGE2 assays required only the growth media, and SRB assays 
required only adherent cells. Optical densities were measured 
at 560  nm wavelength in a 96-well microtiter plate reader and 
baseline readings for controls (empty wells and media only wells) 
were subtracted to yield final O.D. values. The resultant data were 
processed using Excel and Prism software.
Pge2 Detection by liquid 
chromatography-Tandem Mass 
spectrometry
BJ1hTERT or HT1080 cells (300,000) were seeded into T-25 
flasks, incubated overnight and pretreated with DDR inhibi-
tors as above. Supernatants from non-irradiated samples and 
samples irradiated with 3  Gy high LET (70  keV/μm) carbon 
ion IR were collected 48  h post irradiation and stabilized by 
the addition of 0.1% (v/v) butylated hydroxytoluene. The sam-
ples were immediately frozen, stored, and shipped to the CSU 
Center for Environmental Medicine Analytical Laboratory for 
liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis using methods developed to detect PGD2, PGE2, 
and PGF2 (manuscript in preparation).
Pge2 Detection after low or high leT ir 
Under normoxic or hypoxic conditions
HeLa cells were maintained in either normoxic (ambient) or 
1% oxygen concentrations for 72 h after irradiation with low 
LET X-ray, either of two moderately high LET carbon ion 
beams (290 MeV/nucleon monoenergetic beam at 30 keV/μm, 
or 290  MeV/nucleon monoenergetic beam at 70  keV/μm), 
or a higher LET silicon ion beam (135 or 490  MeV/nucleon 
monoenergetic beam at 300 keV/μm). PGE2 in the supernatant 
media was detected by ELISA. Normoxic and hypoxic cells that 
did not receive IR served as controls. Pretreatment with 10 μM 
COX-1/COX-2 inhibitor (Indo) was the same as described 
above.
Functional assay for ir-induced, Pge2-
stimulated growth of co-cultured, 
Unirradiated cells
Twenty-four hours prior to IR, 30,000 (no IR) or 100,000 (to be 
irradiated) HeLa cells were seeded into wells of six-well plates 
and incubated at 37°C in 5% CO2 air. Additionally, 1,000 or 1,500 
HeLa cells were seeded into ThinCert transwell inserts with 
1 μm pores (Greiner), placed into 10 cm dishes and incubated 
at 37°C in 5% CO2 in air. Once cells had attached, transwells 
were transferred into their corresponding wells. Control wells 
were prepared with equal numbers of cells in the transwells but 
no cells below. Twelve hours prior to IR, cells were treated with 
DDR inhibitors and/or Indo as above. Six-centimeter spread 
out Bragg Peak (SOBP) beams of moderately high LET carbon 
ions (290 MeV/nucleon, dose average LET of 50 keV/μm at the 
center of the SOBP) were generated at the Heavy Ion Medical 
Accelerator (HIMAC) facility of the National Institute of 
Radiological Sciences (NIRS), Chiba, Japan. The transwells for 
the irradiated plates were transferred to six-well holding plates 
immediately preceding irradiation and the media in the remain-
ing wells was aspirated. Vertically oriented plates containing the 
cells were irradiated with 4  Gy carbon ion IR. Following irra-
diation, fresh media containing DDR inhibitor was added to the 
wells and the transwells, and the transwells were returned to their 
previous position. For the no IR controls, the media (in wells 
and transwells) was aspirated and fresh media containing DDR 
inhibitor was added and dishes were incubated for 3–6 days. On 
day 3 or day 6 post-irradiation, PGE2 concentrations in transwell 
media was analyzed by ELISA. On day 7, sufficient media was 
added to transwells to allow cell growth for two more days, and 
on day 9 post-irradiation, transwell cells were trypsinized, and 
resuspended in 500–1000 μL of PBS and counted using a Coulter 
Counter or Scepter cell counting device (EMD Millipore).
analysis of apoptosis by caspase 3/7 
cleavage and annexin V assays
Duplicate dishes were prepared for apoptosis assays as follows. 
Twenty-four hours prior to IR, 60,000 (no IR control) or 250,000 
(to be irradiated), HeLa cells were seeded into wells of six-well 
plates and incubated at 37°C in 5% CO2 in air. Twelve hours 
prior to IR, cells were treated with DDR and/or COX-1/COX-2 
inhibitors and irradiated in parallel as described in the previ-
ous section. Following irradiation cells were incubated for 72 h 
and subsequently assayed by flow cytometry for two apoptosis 
endpoints. Caspase 3/7 cleavage/activation was monitored by 
cleavage of a DEVD peptide substrate conjugated to Alexafluor 
488 (Cell Event 3/7 Caspase Green Reagent, Life Technologies) 
as follows. Cells from non-irradiated and irradiated treatment 
groups were trypsinized, harvested, and combined with super-
natants from each well (containing potential apoptotic cells), 
centrifuged at 1200 rpm for 5 min, and the media was removed 
by aspiration. Cells were suspended in 500 μL of fresh media 
containing 1 μL Cell Event reagent (4 μM final concentration) 
and incubated at 37°C in 5% CO2 in air for 15 min, then 500 uL 
of PBS was added to each sample and cells were analyzed on a 
BD FACSCaliber flow cytometer using 488  nm excitation and 
collecting fluorescent emissions with a 530/30 filter set. Gates 
were set using unstained and no treatment/no IR cells as negative 
control populations. Data represent the percent caspase-positive 
cells among 10,000 cells analyzed per sample. Data were acquired 
with CellQuest (Becton Dickinson) software, and analyzed using 
FloJo (Version 7.6.5, Tree Star Inc.) and Prism (Version 5.04, 
GraphPad) software.
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Annexin V (AV) is a Ca2+-dependent phospholipid binding 
protein that binds with high affinity to phosphatidyl serine 
residues that have translocated to the outer leaflet of the plasma 
membrane as a result of upstream apoptotic signaling, represent-
ing an early marker of apoptosis. Propidium iodide (PI) is a cell 
impermeant DNA binding dye that will penetrate into cells with 
compromised (leaky) membranes indicative of cellular necrosis, 
representing late-stage apoptosis. It is possible to discriminate the 
early (AV only), middle (AV and PI double positive), and late 
(PI-positive only) stages of cell death by co-staining with AV and 
PI. Approximately 5 ×  105 cells (and supernatants containing 
potential apoptotic cells) were harvested from wells processed as 
above to generate cell pellets which were washed once in cold PBS, 
harvested by centrifugation, and suspended in 500 μL annexin 
binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 
7.4) yielding cell concentrations of approximately 1 × 106 cells/
mL. Three microliters of Annexin V, Alexa Fluor 488® conjugate 
(Life Technologies) and 150 μL of annexin binding buffer were 
aliquoted to flow cytometry tubes, and 150 μL of cell suspensions 
were added, samples were mixed, incubated at room temperature 
for 15 min, and an additional 300 μL of annexin binding buffer 
was added, samples were mixed, stored on ice, and analyzed on 
a BD FACSCaliber flow cytometer using 488 nm excitation and 
collecting fluorescent emissions for FL1 and FL2 parameters 
using 530/30 and 585/42 filter sets, respectively. Compensation 
was established using the single-stained samples for the +IR 
treatment group and quadrant gating was established to identify 
AV−/PI− (apoptosis negative), AV+/PI− (early apoptotic), AV+/PI+ 
(middle apoptotic), and AV−/PI+ (late apoptotic/necrotic) popu-
lations. Data represent the percentage of cells in each quadrant 
from 5,000–10,000 cells collected per sample, using data acquisi-
tion and analysis software as above.
clonogenic cell survival assay
T25 flasks were seeded to ~20% confluence with cell lines to be 
tested, and incubated overnight. Cells were pretreated with DDR 
inhibitors at least 12 h prior to exposure to low or high LET IR. 
Cells were irradiated at ~50% confluence and allowed to recover 
for 30 min before they were trypsinized, harvested, suspended in 
fresh media, and counted using a Coulter Counter. Appropriate 
numbers of cells to yield ~100 colonies per 6 cm dish were sus-
pended in fresh medium and distributed to three replicate dishes 
per treatment group. Forty-eight hours post irradiation, the media 
was aspirated and replaced with fresh media without drug. The 
cells were incubated for 8–11 days to allow colonies to develop. The 
dishes were stained with 0.5% (w/v) crystal violet in 70% methanol 
solution and the colonies were counted. Survival fractions were 
calculated and plotted using Excel and Prism software. We derived 
p-values for statistical analysis by using student’s t-tests.
resUlTs
Pge2 Production and cell Viability after ir 
Vary among cell Types and are regulated 
by the DDr
The goals of this study were to determine whether DDR inhibitors 
and/or oxygen alter PGE2 production and cell growth of irradiated 
cells in response to low and high LET ionizing radiation. We 
initially surveyed PGE2 production in five cancer cell lines 
(HT1080 fibrosarcoma, HCT116 colorectal carcinoma, MCF7 
breast adenocarcinoma, HeLa cervical adenocarcinoma, and B16 
mouse melanoma) and two normal cell lines (BJ1hTERT, hTERT-
immortalized human foreskin fibroblasts, and HFL3 spontane-
ously immortalized human fetal lung cells) following exposure to 
low LET γ-rays or X-rays. In the absence of DDR inhibitors, PGE2 
levels increased several fold 24 or 48 h after 10 Gy γ-rays with 
most cell lines, with statistically significant differences in MCF7 
and BJ1hTERT, and trending toward significance in HT1080 
(p = 0.06); HCT116 showed an approximately eightfold increase 
at 48 h, but significance could not be calculated because only a 
single determination was made at this time point (Figure 2A). 
In parallel with the PGE2 assays, we measured cell survival/
proliferation by SRB assay and found significant increases in cell 
number 48 h after IR in HT1080 and BJ1hTERT, but not HCT116 
nor MCF7 (Figure 2A). PGE2 effects on growth were previously 
observed at later times after IR (>5 days) (2) so the absence of a 
consistent early growth effect is not surprising. These PGE2 effects 
were observed at IR doses of 3–10 Gy, higher than the 2 Gy doses 
typically used in fractionated photon RT, but well within the 
range of doses used in hypofractionated stereotactic body RT. 
PGE2 production is likely proportional to levels of caspase activa-
tion (and apoptosis), but more studies are required to determine 
whether PGE2 production follows a standard dose–response or 
displays threshold effects. These data demonstrate that basal and 
IR-induced PGE2 levels, and early effects on survival/prolifera-
tion, vary among cell types.
DNA damage response inhibitors affected IR-induced PGE2 
production that again varied among cell types. In control experi-
ments, we confirmed that inhibitors of DNA-PK, ATM, and 
Chk1 reduced clonogenic survival (Figure S2 in Supplementary 
Material and data not shown). DNA-PKi slightly increased 
PGE2 production in HT1080 cells 48 h after IR, but the differ-
ence was not significant, and DNA-PKi had no effect on PGE2 
production in HCT116, MCF7, or BJ1hTERT cells (Figure 2A). 
ATMi suppressed PGE2 levels in HT1080 cells 48 h post IR by 
~1.5-fold, but ATMi did not affect PGE2 in other cell types. Chk1i 
significantly enhanced PGE2 production in HCT116, but other 
cell types showed no Chk1i effects. At 48 h after IR, ATMi dra-
matically decreased cell number (by ~20-fold) of both HT1080 
and BJ1hTERT cells, whereas HCT116 and MCF7 cells were not 
affected. Because the SRB assay provides an estimate of survival/
proliferation based on the amount of protein in attached cells 
(29), the sharp decrease in the number of attached HT1080 and 
BJ1hTERT cells with ATMi reflects massive cell death/detachment 
in response to the combined IR + ATMi treatment. Note that in 
both HT1080 and BJ1hTERT cells ATMi sharply reduced PGE2, 
but only HT1080 showed reduced cell numbers, suggesting that 
PGE2 is reduced by distinct mechanisms in these cell lines, with 
death and detachment preceding PGE2 production in HT1080, 
but not BJ1hTERT.
Prostaglandin E2 production depends on COX1–2 (Figure 1A) 
that can be inhibited with Indo. We next measured PGE2 and cell 
survival/proliferation with HeLa, B16, BJ1hTERT, and HFL3 cells 
48 h after 3 or 10 Gy doses of X-rays in presence or absence of Indo 
FigUre 2 | Pge2 production and short-term cell viability/proliferation in response to γ-rays or X-rays in the presence or absence of DDr or cOX 
inhibitors. PGE2 and cell growth were measured by ELISA and SRB assay in response to (a) 10 Gy γ-rays or (B) 3 or 10 Gy X-rays in the presence or absence of 
indomethacin (Indo). Data are averages ±SD for two to four replicates per treatment group (a) or single determinations (B). In this and all subsequent figures, 
statistical significance was determined by t-tests, * indicates p < 0.05, **p < 0.01, ***p < 0.001.
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(Figure 2B). With HeLa cells, PGE2 levels increased approximately 
fourfold with an X-ray dose of 3 Gy, and approximately twofold 
with 10  Gy. B16 cells produced very little PGE2 without IR or 
with a 3 Gy X-ray dose, but PGE2 increased eightfold at 10 Gy. 
HFL3 and BJ1hTERT cells had high basal levels of PGE2 that 
did not change substantially in response to X-rays. Uniformly, 
Indo dramatically suppressed PGE2 levels (>20-fold), including 
basal and X-ray induced levels in both cancer and normal cells 
(Figure 2B). These data concur with numerous studies showing 
that inflammatory prostaglandin production can be mitigated by 
COX1–2 inhibitors (30). The variable basal levels of PGE2 among 
cell lines may reflect differential expression or activation of PGE2 
pathway proteins, including caspase 3, which may be activated 
when rapidly growing cells reach confluence and deplete growth 
media. There was a general trend toward decreased cell growth 
with increased IR dose. HeLa cells showed both stronger PGE2 
induction with X-rays, and greater radioresistance than the other 
cell lines. Note that HFL3 cells showed poor viability/proliferation 
after IR, and high basal PGE2 levels, yet PGE2 was not induced 
with IR in these cells. These features may be specific to HFL3 cells 
or perhaps reflect general properties of fetal cells.
To determine if low and high LET IR produce similar PGE2 
responses, absolute PGE2 levels in media from HT1080 and 
BJ1hTERT cultures were determined by LC-MS/MS in response 
to 3  Gy high LET (70  keV/μm) carbon ions (Figure  3). This 
alternate PGE2 assay helped us validate and expand on findings 
FigUre 3 | Pge2 production in response to high leT ir ± DDri. LC-MS/MS was used to quantify PGE2 levels in supernatants from HT1080 and BJ1hTERT 
cultures after irradiation with 3 Gy carbon ions (70 keV/μm). (a) Absolute PGE2 levels. (B) PGE2 levels were derived by subtracting the baseline values (no IR, no 
drug); n.d., not determined.
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from the ELISA assay. In the absence of DDR inhibitors, HT1080 
cells showed robust PGE2 induction with carbon ions, similar to 
the effect of low LET IR, and BJ1hTERT cells were unresponsive 
to both low and high LET IR (Figures  2 and 3). These results 
indicate that PGE2 production is stimulated by both low and high 
LET IR in a cell-type-dependent manner. The variation in abso-
lute basal levels of PGE2 in BJ1hTERT cells measured by LC-MS/
MS and ELISA may reflect different sensitivities of ELISA and 
LC-MS/MS assays.
Inhibition of DNA-PK and ATM decreased carbon ion-
induction of PGE2 in HT1080 cells. The decrease in PGE2 with 
DNA-PKi after high LET contrasts with that seen with γ-rays. 
This difference in DNA-PKi effects with low and high LET 
IR could reflect DNA-PK’s dual role in damage signaling and 
DSB repair by NHEJ (Figure 1B), in particular, the shift from 
NHEJ-dominant repair of low LET IR damage to HR-dominant 
repair of high LET damage (31–33). By contrast, Chk1 inhi-
bition markedly increased PGE2 in BJ1hTERT cells, with or 
without IR. The Chk1i effect in the absence of IR suggests that 
the cytotoxicity of Chk1i alone is sufficient to trigger Phoenix 
Rising. This Chk1i effect may reflect aberrant signaling to the 
p53-directed apoptotic cascade culminating in PGE2 produc-
tion, since p53 is stabilized by Chk1 phosphorylation of several 
sites after DNA damage (34). Together the results indicate that 
PGE2 production following low or high LET IR can be enhanced 
or suppressed by inhibition of different pathways in the DDR 
network.
ir-induced Pge2 stimulates Proliferation 
of co-cultured, Unirradiated cells that 
can be Modulated by DDr and cOX1–2 
inhibitors
A transwell multiple-endpoint assay system was used to examine 
the effects of low and high LET IR on co-cultured irradiated and 
unirradiated cells (Figure  4A). The pore size of the transwell 
membranes allows free diffusion of small molecules, but cell 
migration is blocked. This system allows simultaneous analysis of 
FigUre 4 | (a) Transwell multiple-endpoint assay system. Cells were seeded into the top (500–1,500 cells) and bottom (feeder, 100,000 cells) sections of the 
transwell system and incubated for 24 h. The top section was transferred to a separate dish while the bottom section was irradiated, and then replaced. PGE2 was 
measured in the media 3 and 6 days after IR; growth of unirradiated cells was determined 7–9 days after IR. Apoptotic endpoints (caspase 3/7 activation, Annexin V, 
and membrane changes by propidium iodide staining) were measured at 3, 6, or 9 days post IR in irradiated feeder cells. When used, DDR or cyclooxygenase 
inhibitors were present during the entire experiment. (B) HeLa cells assayed for growth stimulation using the transwell assay system after irradiation with 10 Gy low 
LET γ-rays. Indomethacin (Indo) inhibits COX1–2 and suppresses PGE2 production.
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PGE2 production, apoptosis, and cell growth as a key functional 
endpoint. We assessed the effects of radiation quality, DDR and 
COX1–2 inhibitors, and oxygen concentration on these end-
points. We chose HeLa cells for these studies because the cell 
line survey showed that HeLa cells have low basal PGE2 levels, 
and relatively robust PGE2 production after IR that is blocked by 
cyclooxygenase inhibition. A preliminary test of cell prolifera-
tion of unirradiated co-cultured cells 7 days after “feeder” cells 
received 10  Gy γ-rays showed a 2.7-fold increase in growth 
compared to control with mock-irradiated feeder cells, and that 
COX1–2i suppressed this growth (Figure  4B). This result is 
similar to a prior report in which luciferase-expressing cancer 
cell growth was enhanced two- to fivefold when in direct contact 
with irradiated feeder cells (2). The transwell system eliminates 
any influence of cell-to-cell contact, measuring only the growth 
effects of diffusible factors through the transwell membrane.
To investigate whether high LET IR would elicit similar growth 
effects on co-cultured unirradiated cells, we used the transwell 
system to monitor PGE2 production and cell growth in response 
to 70 keV/μm carbon ions. We also tested whether DDR inhibi-
tors and/or the COX1–2 inhibitor Indo would modulate growth 
stimulation. PGE2 production and growth of unirradiated HeLa 
cells was measured 6 days after IR. PGE2 levels increased >20-fold 
in response to IR in the absence of inhibitors (Figure 5A), similar 
to the increase seen with X-rays (Figure 2B). Both DNA-PKi and 
ATMi significantly decreased IR-induced PGE2 levels (approxi-
mately fourfold), and these were further reduced by approximately 
twofold by Indo (Figure 5A), although the latter differences were 
not statistically significant. Growth of unirradiated co-cultured 
HeLa cells was also monitored 6 days after IR. At this time point, 
moderate effects on growth were observed in the absence of 
DDR inhibitors, DNA-PKi increased growth but ATMi had no 
effect (Figure 5B). The increased growth with DNA-PKi does not 
appear to correlate with the lower PGE2 level, but we note that 
PGE2 levels were approximately twofold higher with DNA-PKi 
than untreated cells 3 days after IR (data not shown); the growth 
stimulation seen 6  days after IR may reflect this early burst of 
PGE2, and the higher PGE2 levels without DNA-PKi 6 days after 
IR would enhance growth at later times. The increased growth 
with DNA-PKi relative to untreated cells was dependent on 
feeder cells; no growth stimulation occurred without feeder cells 
(Figure 5C). As expected, blocking PGE2 production with Indo 
(Figure  5A) also blocked growth stimulation (Figures  5A,B). 
As noted above, inhibiting DNA-PKcs or ATM radiosensitized 
cells (Figure S2 in Supplementary Material); thus, the differences 
in PGE2 and growth effects with DNA-PKi and ATMi cannot be 
traced to differential degrees of cell killing, suggesting that inhibi-
tion of different DDR pathways can differentially affect Phoenix 
Rising and death pathway choice.
The transwell assay system is versatile in that in addition to 
PGE2 and growth, simultaneous measures of apoptotic stages can 
be determined with the same cultures, including early apoptosis 
(caspase cleavage, detected with a cell-permeable caspase 3/7 
DEVD peptide conjugated to a quenched fluorophore, which 
becomes fluorescent upon peptide cleavage), mid-apoptosis 
(Annexin V staining), and late apoptosis (revealed as gross 
membrane changes with propidium iodide staining). These 
endpoints were measured 3 and 6 days after high LET IR by flow 
FigUre 5 | Pge2 production and stimulated proliferation of unirradiated hela cells in response to high leT carbon ions. (a) ELISA measurements from 
media in transwells containing HeLa cells 6 days after 0 or 4 Gy carbon ion irradiation. (B) Relative growth of unirradiated cells in transwells with or without DDR 
inhibitors or indomethacin, 6 days after irradiation of feeder cells. (c) As in (B) but without feeder cells. Data are averages (±SEM) for two determinations per 
condition.
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cytometry (Figure 6). Minimal caspase activation was detected in 
unirradiated controls, and ~30% of cells activated caspase 3 and 
6 days after IR. DDRi and Indo moderately suppressed caspase 
activation at both time points. Caspase is activated upstream of 
arachidonic acid that is processed by the Indo target, COX1–2, 
in the Phoenix Rising pathway (Figure  1A). This raises the 
possibility of a caspase–COX1–2 feedback loop, although the 
present experiments cannot rule out off target effects of Indo. 
Strikingly, ATMi appeared to completely block progression to 
later apoptotic stages; to a lesser extent DNA-PKi and Indo also 
suppressed progression to later apoptotic stages. Since ATMi is 
a strong radiosensitizer, the lack of progression to late apoptosis 
indicates that cells are shunted to one or more alternative death 
or senescence pathways.
robust Phoenix rising responses in cell 
lines Derived From Fresh Tumor Tissue
Cell lines freshly derived from patient tumor tissue have emerged 
as important models for cancer cell biology studies (28, 35–37). We 
chose HNSCC-derived cell lines because head and neck cancers 
are treated with low and high LET RT. Low passage tumor cell lines 
were tested within 3 months of culture expansion. Two cell lines, 
CUHN036 and CUHN065, senesced or grew too slowly to study. 
Two others, CUHN013 and CUHN067, were reproductively 
robust and viable throughout the course of the experiments. 
CUHN013 is from a moderately focally keratinizing submental 
mass tumor. CUHN067 is from a base of tongue tumor that 
displayed extensive perineural invasion. Radiosensitivity was 
evaluated by clonogenic survival after X-rays or a clinical, 6 cm 
SOBP, high LET (~50 keV/μm) carbon ion beam. CUHN013 was 
more radiosensitive than CUHN067 to both X-rays and carbon 
ions, and both cell lines showed typical carbon ion RBEs of ~2–3 
(Figure S3B in Supplementary Material).
Doses of 4 Gy SOBP carbon ions significantly increased cas-
pase 3/7 activation compared to mock-irradiated controls, and 
DDRi and Indo had little effect on this endpoint (Figure 7A). 
These results demonstrated that the initiating event of 
Phoenix Rising was functioning in these clinically relevant 
models. As with HeLa, in transwell experiments the CUHN 
cell lines showed moderate to strong growth stimulation of 
unirradiated cells that was dependent on irradiated feeder cells 
(Figures  7B–E). Neither CUHN cell line showed significant 
alterations in growth with DDRi or Indo. These early (caspase 
activation), late (growth stimulation, suppressible with Indo) 
Phoenix Rising markers indicate that Phoenix Rising is func-
tioning in CUHN067. By contrast, CUHN013 displayed the 
early caspase marker and modest, but statistically significant 
(p < 0.01) growth stimulation, but Indo failed to suppress this 
growth, suggesting a late-stage defect. The distinct phenotypes 
of the two CUHN cell lines, in radiosensitivity and growth 
responses with or without inhibition of DNA-PK or COX1–2, 
highlight the challenges associated with targeting DDR and 
Phoenix Rising pathways for precision medicine.
Oxygen concentration and leT attenuate 
Pge2 Production after exposure to carbon 
or silicon ion Beams
COX1 and COX2 require sufficient oxygen to function efficiently. 
A number of tumor types are naturally hypoxic and/or have 
hypoxic regions. We tested the hypothesis that hypoxic cells will 
produce less PGE2 after IR than normoxic cells due to impaired 
COX1–2 function (Figure 1A). HeLa cells were incubated under 
normal conditions (5% CO2 in air, ~20% oxygen), or hypoxic con-
ditions (1% oxygen) for 72 h after IR and PGE2 production was 
determined by ELISA. Normoxic and hypoxic cultures that did 
not receive IR served as controls. As above, 10 Gy X-irradiation 
increased PGE2 production by ~20-fold under normoxic condi-
tions, but this was significantly reduced (to less than fivefold) 
under hypoxic conditions (Figure 8). Oxygen concentration had 
no effect on PGE2 levels without IR. We next tested the effects 
of oxygen on particle radiation at three LET values, 30 keV/μm 
carbon ion, 70 keV/μm carbon ion, and 300 keV/μm silicon ions. 
FigUre 6 | Flow cytometric analysis of apoptotic phenotypes of feeder cells (from Figure 5) irradiated with high leT carbon ion ir. Duplicate plates 
were irradiated in parallel for assays 3 days post IR. Feeder cells co-cultured with transwell inserts were assayed 6 days post IR. Each sample was split at the time 
of harvest for two assay endpoints. Caspase cleavage and activation was assayed in live cells (a) 3 or (D) 6 days post IR using a fluorescent caspase 3/7 peptide 
fragment. Annexin V/propidium iodide co-staining of fixed cells discriminates between early, mid, or late apoptotic stages and was assayed (B) 3 or (e) 6 days post 
IR. No IR controls for the annexin V/PI assay (c) 3 or (F) 6 days post IR; ~10,000 cells were interrogated per determination. Unstained cells served as negative 
controls.
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In all cases, hypoxia markedly reduced PGE2 production, and 
with 30 or 70 keV/μm carbon ions, treatment with Indo further 
reduced PGE2 production, in both normoxic and hypoxic treat-
ment groups (Figure  8). Interestingly, 70  keV/μm carbon ions 
consistently caused approximately two- to threefold greater 
induction of PGE2 than 30 keV/μm carbon ions under normoxic 
or hypoxic conditions, and in the presence or absence of Indo. 
While this suggests an LET dependence for PGE2 production, 
this is questionable given that PGE2 induction was greatest with 
low LET X-rays, and that the highest LET radiation (300 keV/μm 
silicon ions) induced PGE2 no more than 70 keV/μm carbon ions; 
this parallels earlier findings that RBE peaks at 150–200 keV/μm. 
Further studies are required to determine whether LET depend-
ence follows a complex pattern (e.g., plateaus above a certain 
LET), and whether there are signaling differences with photons 
vs. particle radiation that account for the high level of PGE2 
FigUre 7 | caspase activation and relative growth in two hnscc cell lines after exposure to 4 gy high leT ir. (a) Caspase cleavage and activation was 
assayed in live cells 48 h post IR. (B,D) Relative growth of primary tumor cells from transwells 6 days post IR with or (c,e) without irradiated feeder cells. Data 
represent the averages and SDs for three replicate measurements per determination.
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induction with X-rays. Our results clearly indicate that, regardless 
of radiation quality, PGE2 production is very sensitive to oxygen 
concentration. Thus, hypoxic tumor regions are unlikely to con-
tribute to tumor repopulation via Phoenix Rising.
DiscUssiOn
The Phoenix Rising pathway correlates with tumor repopulation 
in vitro and in vivo (27, 38, 39). The present study revealed several 
important features of IR-induced PGE2 responses of normal and 
cancer cells. IR-induced, caspase 3-dependent, PGE2 production 
(whether associated with apoptosis or other death pathways), is 
a common response of irradiated tumor cells, and some normal 
cells. PGE2 levels generally enhanced growth of neighboring 
viable cells. Such growth, if unchecked, could spawn cells with 
high mutation rates, through replication of damaged genomes, 
as well as by an alternative mechanism activated in cells with 
moderately active caspase 3, that induces genome instability and 
carcinogenesis (40). Such small- and large-scale genetic change 
can drive rapid evolution of tumors, converting a local problem 
into lethal metastases.
Here, we focused on PGE2 production, cell viability, and prolif-
eration of irradiated and unirradiated cells in response to signaling 
factor(s) from co-cultured irradiated, apoptotic “feeder” cells; the 
modulation of these responses by DDR and COX1–2 inhibition 
and by varying oxygen concentration; and the effects of radiation 
quality. Interconnected DDR and growth pathways coordinate 
responses radiation and chemotherapy-induced DNA injury and 
conspire with programed cell death pathways to determine cell 
fate (Figure 1B). In this study, we found that PGE2 production 
and growth responses varied among cancer and normal cell lines, 
including cell lines freshly derived from patient tumors.
Although DDR inhibition enhanced radiosensitivity (Figure 
S2 in Supplementary Material), this did not correlate with 
a single pattern (increase or decrease) in PGE2 production. 
Inherent radiosensitivity, and DDRi effects on radiosensitivity, 
varies widely among different cell types (4, 41) as observed here 
(Figures S2 and S3 in Supplementary Material). In general, the 
effects of radiation on the various endpoints (caspase activation, 
PGE2 production, growth) were consistent across all radiation 
types tested. This suggests that targeting PGE2-driven accelerated 
tumor repopulation may be an effective adjunct to both photon 
and particle radiotherapies. A fairly common response of ATMi 
and DNA-PKi was suppression of PGE2 production. A plausible 
explanation for this effect stems from the observations that ATM 
and DNA-PK activate the NFκB transcription factor in response 
to IR and other genotoxins (42–45), and COX-2, the upstream 
regulator of PGE2, is one of many NFκB targets (46). Because of 
the extensive crosstalk between DDR and growth factor networks, 
considerably more effort is required to define the multitude of 
FigUre 8 | ir-induced Pge2 production is suppressed by hypoxia. PGE2 levels were determined by ELISA 3 days after X-ray, silicon ion, or carbon ion 
radiation at indicated LET and doses. Cells were incubated under normoxic, or hypoxic (1% O2) conditions. Data represent the averages and SDs for nine replicate 
measurements per determination.
December 2015 | Volume 5 | Article 26012
Allen et al. Regulation of Radiation-Induced Growth Factor Release
Frontiers in Oncology | www.frontiersin.org
tumor type responses to genetic and chemotherapeutic manipu-
lation of DDR/growth regulatory factors. Phenotypic patterns 
emerging from such studies will guide mechanistic understand-
ing of these various pathways, and may lead to rapid, inexpensive 
screening tools that will inform RT practice.
One facet that is consistent throughout our study and several 
others (2, 27, 47) is caspase activation and PGE2 production. 
This is important because caspase status in tumors correlates 
with patient survival: patients with caspase 3-positive tumors 
do not survive as long as those with caspase 3-negaitve tumors 
(2, 48, 49). In addition, a recent study showed that low doses 
of radiation cause partial caspase 3 activation that leads to 
genome instability in vitro and in vivo through the generation 
of persistent DNA strand breaks (40). Another recent study 
demonstrated that caspase 3 defects created by shRNA, domi-
nant negative gene expression, or gene deletion suppressed 
tumor growth in vitro and in vivo (47). Together, these findings 
implicate caspase 3 as a promising target to improve chemo-
therapy or RT outcomes.
COX1 and COX2 are also promising targets to enhance cancer 
therapy. The present study and others (2, 40, 47, 50) demonstrate 
that PGE2 production and stimulated growth can be effectively 
suppressed by Indo and other COX1 and COX2 inhibitors. Non-
steroidal anti-inflammatory compounds (NSAIDS) effectively 
target cyclooxygenase enzymes and are generally safe. Our 
study focused on Indo, a pan-COX1–2 inhibitor; other well-
characterized examples are Naproxen and Ibuprofen, which are 
widely used and well tolerated. Selective COX2 inhibitors, such 
as Celecoxib, have been marketed but many have been withdrawn 
due to increased risk of myocardial infarction; it is possible 
that such risk is minimal for short-term courses during cancer 
therapy. A body of literature is beginning to emerge that describes 
tests of cyclooxygenase inhibitors in combination with RT or 
chemotherapy. In one study, Celecoxib delivered between rounds 
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of gemcitabine and cisplatin substantially suppressed bladder 
urothelial carcinoma xenograft regrowth, and enhanced the 
chemotherapeutic response in xenografts from a chemoresistant 
patient (7). An earlier study of LNCaP-COX2 mouse xenografts 
showed that topical application of the NSAID Diclofenac signifi-
cantly reduced tumor growth in combination with 3 Gy IR (51).
Finally, we demonstrate that PGE2 production in response 
to IR is highly sensitive to oxygen concentration, including low 
and high LET radiation. Hypoxic regions of tumors are typically 
resistant to low LET IR. By contrast, high LET IR has a minimal 
oxygen enhancement ratio and, therefore, has greater efficacy 
than photons against these hypoxic regions (52). PGE2-stimulated 
tumor repopulation may not be a critical issue to consider during 
treatment planning for hypoxic regions of tumors. We stand at a 
new frontier on the path toward personalized precision medicine. 
As basic scientists and clinicians look to improve the efficacy and 
safety of cancer treatment in the future, it will be important to 
develop techniques for rapid, accurate detection of Phoenix Rising 
biomarkers to personalize patient care. Preventing accelerated 
tumor repopulation during RT and chemotherapy will improve 
local control and reduce the likelihood that early stage cancer will 
progress to more dangerous invasive and metastatic stages.
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